C4 Therapeutics annual net debt
2019
2020
2021
2022
2023
2024
2025
C4 Therapeutics Net Debt Growth & History (CCCC)
C4 Therapeutics's net debt was −$14.6M for fiscal 2025.
View full C4 Therapeutics company overviewC4 Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$14.6M | −$24.9M | — |
| 2024 | 2024-12-31 | $10.3M | $65.9M | — |
| 2023 | 2023-12-31 | −$55.6M | −$113.0M | — |
| 2022 | 2022-12-31 | $57.4M | $90.6M | — |
| 2021 | 2021-12-31 | −$33.2M | $125.6M | — |
| 2020 | 2020-12-31 | −$158.8M | −$82.0M | — |
| 2019 | 2019-12-31 | −$76.8M | — | — |
C4 Therapeutics quarterly net debt
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$21.8M | −$6.5M | — |
| Q1 2026 | 2026-03-31 | −$2.8M | −$15.9M | — |
| Q4 2025 | 2025-12-31 | −$14.6M | −$24.9M | — |
| Q3 2025 | 2025-09-30 | $2.7M | −$4.8M | −64.36% |
| Q2 2025 | 2025-06-30 | −$15.2M | −$10.5M | — |
| Q1 2025 | 2025-03-31 | $13.1M | $33.0M | — |
| Q4 2024 | 2024-12-31 | $10.3M | $65.9M | — |
| Q3 2024 | 2024-09-30 | $7.4M | −$3.8M | −33.58% |
| Q2 2024 | 2024-06-30 | −$4.7M | −$43.5M | — |
| Q1 2024 | 2024-03-31 | −$19.9M | −$55.9M | — |
| Q4 2023 | 2023-12-31 | −$55.6M | −$113.0M | — |
| Q3 2023 | 2023-09-30 | $11.2M | −$27.3M | −70.88% |
| Q2 2023 | 2023-06-30 | $38.8M | $9.8M | +33.79% |
| Q1 2023 | 2023-03-31 | $36.0M | −$5.4M | −13.14% |
| Q4 2022 | 2022-12-31 | $57.4M | $90.6M | — |
| Q3 2022 | 2022-09-30 | $38.5M | $178.6M | — |
| Q2 2022 | 2022-06-30 | $29.0M | $287.4M | — |
| Q1 2022 | 2022-03-31 | $41.4M | $113.5M | — |
| Q4 2021 | 2021-12-31 | −$33.2M | $125.6M | — |
| Q3 2021 | 2021-09-30 | −$140.1M | −$99.6M | — |
| Q2 2021 | 2021-06-30 | −$258.4M | — | — |
| Q1 2021 | 2021-03-31 | −$72.1M | — | — |
| Q4 2020 | 2020-12-31 | −$158.8M | −$82.0M | — |
| Q3 2020 | 2020-09-30 | −$40.5M | — | — |
| Q4 2019 | 2019-12-31 | −$76.8M | — | — |
C4 Therapeutics net debt trends
Over the last five fiscal years, C4 Therapeutics's net debt increased from −$158.8M to −$14.6M, a change of $144.2M. The latest reported quarter, Q2 2026, shows −$21.8M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review C4 Therapeutics source filings ↗